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How to deal with uncertainties regarding the 
occupational exposure to antineoplastic mixtures.   
Additive effect should always be considered? 
RISK ASSESSMENT CONSIDERATIONS 
 
The concept that “safe levels of exposure” for humans can be identified for 
individual chemicals is central to the risk assessment of compounds with known 
toxicological profiles. 
 
Selection of agents for combination chemotherapy regimens involves minimize 
overlapping of mechanisms of action, antitumor activity and toxicity profile.  
 
Although the toxicological profile and mechanism of action of each individual drug is 
well characterized, the toxicological interactions between drugs are likely, but poorly 
established at occupational exposure context.  
 
The synergistic nature of interactions may help in understanding the adverse 
health effects observed in healthcare workers, where exposure situations are 
characterized by complex mixtures of chemical agents, and the levels of individual 
exposing agents are often not sufficiently high to explain the health complaints. 
However, if a substance is a genotoxic carcinogen, this would be the “lead effect”; 
normally, no OEL based on a NOEL would be derived and the level would be set so low 
that it would be unlikely that other effects would be expected.  
 
OCCUPATIONAL EXPOSURE TO ANTINEOPLASTIC AGENTS 
 
Antineoplastic agents are genotoxic agents, meaning that occupational exposure is 
considered an unacceptable risk, which is considered intolerable, whatever the benefit.  
However, and due to the high need of these drugs for cancer treatment their use is 
unavoidable. Therefore, between the acceptable and unacceptable risks we have to 
consider the tolerable risk, where a balance has to be found between risk and benefit.  
 
Health care workers (e.g. pharmacists, pharmacy technicians, nursing personnel or 
environmental services), may be exposed to these agents in the air, on work surfaces, 
contaminated clothing, medical equipment, patient excreta, and other surfaces since 
they work in areas where occurs the preparation or administration of these agents. 
 
ACGIH® adopts the approach that the combined effect of a mixture of two or more 
hazardous substances, which act on the same organ, should be given primary 
consideration, rather than the effects of each substance individually. In the absence of 
information of the contrary, the effects of the different hazards should be considered 
as additive.  
 
INTRODUCTION 
Recently research project developed in Portuguese Hospitals characterize the occupational exposure to antineoplastic agents and the health effects related. The project aimed to assess 
exposure of the different risk groups that handle antineoplastic agents in the hospital setting, namely during preparation and administration of these drugs. Here it is presented and 
discussed the results in a study developed in two hospitals from Lisbon.  
STUDY DEVELOPED 
RESULTS 
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MATERIAL AND METHODS 
Genotoxicity assessment: The peripheral blood was obtained by venipuncture from 46 
workers occupationally exposed to antineoplastic drugs, namely: pharmacists, 
pharmacy technicians and nurses from two hospital pharmacies and three oncology 
wards; and 46 non-exposed (controls).  
Lymphocytes were isolated and cultured for Cytokinesis-Blocked Micronucleus (CBMN) 
assay.  
The studied endpoints were micronucleus, nucleoplasmic bridges and nuclear buds. 
Visualization was made with a Leica DM500 microscope with immersion oil and 1000x 
amplification according to the criteria of classification established and validated by the 
HUman MicroNucleus (HUMN) International Collaborative Project available in 
http://www.humn.org.  
CONCLUSIONS 
Chemical contamination assessment: Cyclophosphamide (CP), 5-fluorouracil (5FU), and 
paclitaxel (PTX) were used as surrogate markers for surfaces contamination.  
 
The surfaces were sampled in the first three months of the year 2013 in two different 
days in each hospital. Data about which drugs were handled was collected.  
 
Surface areas of 100 cm2, defined by a stainless frame with an internal size of 10×10 
cm were wipe-sampled with gauze moistened with ethyl-acetate. The frame was 
cleaned between each sample, and a new pair of gloves was used for each wipe 
sample. Wipe samples were taken and analyzed by HPLC-DAD. 
Considering that nowadays the combined therapy with two or more agents is increasing, it is important to understand that, although the drugs dose is lower, the effects of the 
mixtures should be investigated as additives, and further studies are required in this field. Results obtained claimed attention also to the fact that exposure is probably occurring as a 
mixture and there are procedures that promote this. 
 
As newly developed antineoplastic drugs are designed and introduced, in order to attack specific intracellular targets, their harmful effects could easily “escape” from detection by 
most standard endpoints. The CBMN should be used to accurately evaluate cytogenetic outcomes of such exposures. Its value in the assessment of genotoxic damage among 
occupationally exposed personnel was also confirmed in this study.  
 
These studies are of particular interest to healthcare professionals who has the potential to come in contact with these drugs. Countries like Portugal, which witnessed an increase in 
hospital production in the field of oncological diseases since 2007, resulting in an intensification of occupational exposure to antineoplastic drugs of health care workers in hospital 
cytotoxic circuit, consequence partly by the National Health System hospital centralization process, should be aware to this problem.  
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Hospitals assessed have similar characteristics (Table 1).    
Chemical contamination assessment (Table 2) shows that were analyzed a total of 327 
samples, of which, it was possible to detect and quantify at least one drug in 121. 
Contamination by more than one antineoplastic drug occurred mainly in the administration 
unit. Our results showed contamination by drugs on days when those analytes were not used 
at all in preparation and administration. This probably results from inappropriate cleaning 
procedures that can be related with the detergents used and/or the frequency of the this 
action. 
Genotoxicity assessment (Table 3).  The data obtained has shown a significant increase of 
micronuclei in lymphocytes in the exposed group in comparison with controls, on account of 
genomic instability, as an increased amount of mutations and/or chromosomal aberrations 
that cytogenetically translate into a greater frequency of changes in chromosome and in the 
formation of micronuclei. 
  
MN in BN 
Mean ± S.E. (range) 
NPB 
Mean ± S.E.(range) 
NBUD 
Mean ± S.E. (range) 
Exposed 9.83±1.28 (1-58)* 0.65±0.14 (0-3)* 2.43±0.37 (0-11)* 
Controls 5.09±0.89 (0-34)* 0.11±0.05 (0-1)* 1.37±0.32 (0-13)* 
OR (95%CI) 6.667 (2.369-18.76) 5.770 (1.924-17.307) 2.893 (1.135-7.373) 
Table 3 – MN, NPB and NBUD in the two groups. Association between exposure  and genotoxicity biomarkers 
Hospitals CP 5-FU PTX 
Samples with 
contamination 
Contamination 
with more than 1 
drug 
A 1/67 (1.5%) 17/67 (25.4%) 17/67  (25.4%) 21/67 (31.3%) 13/67 (19.4%) 
B 14/260  (5.4%) 18/260 (6.9%) 54/260 (27.3%) 100/260 (38.5%) 15/260 (5.8%) 
Totals 15/327 (4.6%) 35/327 (10.7%) 71/327 (21.7%) 121/327 (37%) 28/327 (8.6%) 
Hospital A Hospital B 
Mean number of cancer patients 3429 patients/year 100 patients/day 
N.º of nurses in oncology wards 5 5 
N.º of pharmacy technicians 
preparing cytotoxic drugs 
10 9 
N.º of pharmacists 4 5 
Top five drugs 
5-FU; CP; Doxorrubicin; Irinotecan; 
Oxaliplatin 
5-FU; CP; Cisplatin; Methotrexate; 
PTX 
Mean n.º of drug preparations/day 60 250 
Preparation  Class II BSC in a grade B room (two, hospital A; three, hospital B) 
Personal Protective Equipment 
Pharmacy technicians - overshoes, head covering, goggles, mask P2/P3, sterile 
gown, and sterile gloves (two pairs). Pharmacist and nursing staff - one pair of 
gloves 
Table 1 – Main characteristics of the institutions   
Table 2 – Main results of chemical contamination assessment 
Abbreviations: MN - Micronucleus ; BN - NPB – Nucleoplasmic Bridges; NBUD – Nuclear Buds. *Mann-Whitney test (p-value<0.001)   
